The relationship between nesfatin-1 and carotid artery stenosis

References

• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC), and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
   Google Scholar
• Oh IS, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709–712.
   PubMed Web of Science ®Google Scholar
• Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009;297:R330–R336.
   PubMed Web of Science ®Google Scholar
• Dai H, Li X, He T, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2013;46:167–171.
   PubMed Web of Science ®Google Scholar
• Kuyumcu MS, Kuyumcu A, Yayla C, et al. Nesfatin-1 levels in patients with slow coronary flow. Kardiol Pol. 2018;76:401–405.
   PubMed Web of Science ®Google Scholar
• Ding S, Qu W, Dang S, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med Sci Monit. 2015;21:91.
   Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–274.
   PubMed Web of Science ®Google Scholar
• Ferguson GG, Eliasziw M, Barr HWK, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke. 1999;30:1751–1758.
   PubMed Web of Science ®Google Scholar
• Feijoo-Bandin S, Rodriguez-Penas D, Garcia-Rua V, et al. Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level. Endocrine. 2016;52:11–29.
   PubMed Web of Science ®Google Scholar
• Bonnet MS, Pecchi E, Trouslard J, et al. Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus. J Neuroinflammation. 2009;6:27.
   PubMed Web of Science ®Google Scholar
• Tang C-H, Fu X-J, Xu X-L, et al. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012;36:39–45.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874.
   PubMed Web of Science ®Google Scholar
• Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29:1625–1630.
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Neri S, Di Pino L, et al. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. Clin Exp Med. 2001;1:9–12.
   PubMed Web of Science ®Google Scholar
• Ayada C, Turgut G, Turgut S, et al. The effect of chronic peripheral nesfatin-1 application on blood pressure in normal and chronic restraint stressed rats: related with circulating level of blood pressure regulators. GPB. 2015;34:81–88.
   Google Scholar
• van Lammeren GW, den Hartog AG, Pasterkamp G, et al. Asymptomatic carotid artery stenosis: identification of subgroups with different underlying plaque characteristics. Eur J Vasc Endovasc Surg. 2012;43:632–636.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Wada K, Uozumi Y, et al. Adiponectin receptor 1 expression is associated with carotid plaque stability. Neurol India. 2013;61:249–253.
   PubMed Web of Science ®Google Scholar
• Musialek P, Tracz W, Tekieli L, et al. Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis. J Clin Neurol. 2013;9:165–175.
   PubMed Web of Science ®Google Scholar
• Ozkan Y, Timurkan ES, Aydin S, et al. Acylated and desacylated ghrelin, preptin, leptin, and nesfatin-1 peptide changes related to the body mass index. Int J Endocrinol. 2013;2013:236085.
   PubMed Web of Science ®Google Scholar
• Hallberg M. Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors. Med Res Rev. 2015;35:464–519.
   PubMed Web of Science ®Google Scholar
• Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344:1–12.
   PubMed Web of Science ®Google Scholar
• Ukkola O, Poykko S, Paivansalo M, et al. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med. 2008;40:465–473.
   PubMed Web of Science ®Google Scholar
• Koleva DI, Orbetzova MM, Nikolova JG, et al. Pathophysiological role of adiponectin, leptin and asymmetric dimethylarginine in the process of atherosclerosis. Folia Med (Plovdiv). 2016;58:234–240.
   PubMedGoogle Scholar
• Virdis A, Duranti E, Colucci R, et al. Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. Eur Heart J. 2015;36:3023–3030.
   PubMed Web of Science ®Google Scholar
• Koopmann A, Bez J, Lemenager T, et al. Effects of cigarette smoking on plasma concentration of the appetite-regulating peptide ghrelin. Ann Nutr Metab. 2015;66:155–161.
   PubMed Web of Science ®Google Scholar
• Toffolo MCF, Gomes ADS, Van Keulen HV, et al. Alteration of inflammatory adipokines after four months of smoking abstinence in multidisciplinary intervention program. Nutr Hosp. 2018;35:434–441.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972.
   PubMed Web of Science ®Google Scholar